Certara Appoints John Reynders as New Independent Board Member
16 oct. 2024 16h15 HE
|
Certara
Certara today announced the appointment of John Reynders, PhD to its Board of Directors, effective October 15, 2024.
Certara Completes Acquisition of Chemaxon
02 oct. 2024 16h15 HE
|
Certara
Certara completes acquiring Chemaxon, a leading cheminformatics company that develops scientific informatics software used by the life sciences industry.
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug
18 sept. 2024 08h00 HE
|
Certara
Certara shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001.
Certara Launches Phoenix™ Version 8.5 Drug Development Software
15 août 2024 16h15 HE
|
Certara
Certara today announced the launch of Phoenix™ version 8.5 software, the pharmaceutical industry's gold standard in PK/PD modeling and simulation.
Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio
09 juil. 2024 16h45 HE
|
Certara
Certara has signed a definitive agreement to acquire Chemaxon, a leading provider of cheminformatics software.
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software
17 juin 2024 08h00 HE
|
Certara
Certara today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers.
Mammalian Cell Fermentation Technology Market anticipated journey towards the lucrative US$ 68 Billion valuation. At a CAGR of 10% by 2034 | Future Market Insights, Inc.
23 avr. 2024 12h30 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, April 23, 2024 (GLOBE NEWSWIRE) -- The mammalian cell fermentation technology market is estimated to be worth US$ 45.9 billion in 2024 and is projected to be valued at US$ 68 billion by...
Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies
13 déc. 2023 16h30 HE
|
Certara
Combined Certara-Applied Biomath organization establishes the life sciences industry’s largest quantitative systems pharmacology center.
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
21 nov. 2023 16h30 HE
|
Certara
Certara's Simcyp™ Biopharmaceutics software helps biopharmaceutic, formulation & CMC scientists formulate complex new and generic drugs faster and cheaper.
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
19 sept. 2023 08h15 HE
|
Certara
PRINCETON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced it has successfully supported 300 completed submissions to...